FatigFix™- a New Adaptogenic Ingredient for the Relief of Fatigue and Improvement of Sleep Quality

Nottingham, United Kingdom, November 29, 2010 --(PR.com)-- Fatigfix™ is a safe and effective solution for a problem effecting millions of people worldwide. FatigFix™ has been shown in double-blind, placebo-controlled studies of middle aged individuals complaining of fatigue symptoms, to significantly reduce various symptoms of fatigue (lethargy, clarity of thought, frequency of headaches etc.), increase energy levels, and improve the quality of sleep after only a few weeks of taking the product. FatigFix™ is being offered as a functional health food ingredient and can be formulated into various dosage forms including tablets/capsules, stick-pack, and drinks.

Chrysalis Director Mark Broughton commented, “FatigFix™ works as an 'adaptogenic formula' our clinical studies demonstrate not only a reduction in day time fatigue, but also a significant improvement in sleep patterns and quality of sleep.” FatigFix™ is a novel combination of three highly effective plant extracts, each with a well-established history of safe use as adaptogens.

Phynova is seeking to commercialise FatigFix™ in the USA, Far East, Middle East and Africa, Latin America, and some European countries. Enquiries should be made to Phynova’s marketing partners Chrysalis Health & Beauty Business Solutions Limited for details of available markets for the active ingredient and finished product formats.

About Phynova Group Limited: Phynova is a UK company developing prescription pharmaceuticals, OTC drugs (Traditional Medicinal Herbal Products) and functional ingredients for healthcare and personal care markets, that are derived from plants used in Chinese medicines. Phynova specializes in gastroenterology (including hepatology), metabolic disorders and anti-infectives. Phynova’s lead product for postoperative ileus is currently enrolling patients in a Phase II proof-of-concept clinical trial in China. Other products include a candidate for the symptoms of chronic hepatitis C, which has completed a Phase I/II trial in the US and a Phase II trial in the UK; and two further products, a topic antibacterial for MRSA and a treatment for obesity and non-alcoholic fatty liver disease, are targeted for entry to the clinic over the upcoming two years. For further information please visit www.phynova.com

About Chrysalis Health & Beauty Business Solutions Limited. Chrysalis Health & Beauty is a UK company specialist in the sales and marketing of innovative ingredients and products for Pharma, nutraceutical and personal care sectors. For further information please visit www.fatigfix.com/ or contact info@chrysalisweb.com

www.fatigfix.com

###